CorNova, a development-stage endovascular company, has expanded its executive team with the appointment of Robert Gallahue as chief financial officer (CFO) and the addition of Richard Sahagian as senior scientist.
Gallahue has more than 20 years of financial management experience with public and private biotechnology and medical technology companies at various stages of clinical and commercial development, according to the Burlington, Mass.-based CorNova. He has participated in a variety of financial transactions, including initial public offerings, mergers, joint ventures, private placements and follow-on offerings at healthcare companies, including Molecular Insight Pharmaceuticals, Keryx Biopharmaceuticals and LeukoSite.
Sahagian has more than 20 years of experience in medical device development and production. CorNova said that he will be responsible for production of the Valecor Platinum coronary stent (a platinum surface-modified stent), as well as manage the research and development of advanced surface modification technologies. Prior to joining CorNova, Sahagian founded the medical device division at Implant Sciences.
The company said that the appointments reflect the development of its endovascular product line, which includes the FiberHalo stent deployment and post-dilatation balloon catheter, the FiberHalo pre-dilatation balloon catheter and its Valecor Platinum coronary stent system.